Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer
https://www.facingourrisk.org/XRAY/genetic-testing-needed-for-all-with-metastatic-cancer
Full article: https://ascopubs.org/doi/full/10.1200/JCO.20.03661
In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- With my personal and family cancer history, should I consider genetic testing?
- What are the risks and benefits of genetic testing?
- How do I receive genetic counseling?
- I have been newly diagnosed with an inherited mutation in a cancer gene. What options or changes would you suggest for my cancer treatment?
- I have an inherited mutation in a cancer gene. What are my risks of different types of cancer given my mutation status?
Open Clinical Trials
The following studies involve genetic testing in people with advanced cancers:
- NCT01775072: Genomic Profiling in Cancer Patients. This is the ongoing study referenced in this review. This study aims to better understand how genetic changes affect cancer outcomes. Researchers are looking at inherited and tumor mutations .
- NCT03503097: Genetic testing for men with metastatic prostate cancer (GENTleMEN). The goal of this research study is to determine if online genetic education and testing with online genetic counseling is an acceptable method of providing genetic testing to men with metastatic prostate cancer.
- NCT03665295: PROMPT. The goal of the PROMPT Registry is to follow people with mutations or variants in genes found on genetic testing panels so that patients physicians and researchers can more clearly understand other lesser-known risks.
- NCT04353973: A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients (E-Reach). This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home.
The following studies are looking at treatment for people with advanced solid tumors.
- NCT05252390: NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors.This study will test the safety and effectiveness of the experimental drug NUV-868 alone and combined with a PARP inhibitor in people with advanced solid tumors. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.
- NCT02264678: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents. This is a study of ceralasertib administered orally in combination with chemotherapy regimens and/or novel anticancer agents to patients with advanced cancer. The study is enrolling people with inherited mutations, including BRCA1, BRCA2, ATM, RAD51C, RAD51D, and people with tumors that are HRD-positive.
- NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). This research is designed to learn whether treatment with a new PARP inhibitor, AZD5305, used alone or in combination with anti-cancer agents is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors. The study is open to people who have previously been treated with PARP inhibitors.
- NCT04267939: ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer. This study will look at how well people with advanced solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib. This study is open to people with inherited mutations in ATM, BRCA1, BRCA2 and other genes. Contact the study coordinator for information about eligibility for people with mutations in other genes.
- NCT04657068: Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors. This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes that are linked to DNA damage repair. This study is open to people who have an inherited or acquired BRCA or ATM mutation or whose tumors are HRD-positive. This study is open to people whose cancer stopped responding or progressed on PARP inhibitors.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.